medigraphic.com
ISSN 1561-3046 (Electronic)

2020, Number 1

<< Back Next >>

Rev Cub Med Mil 2020; 49 (1)

Ophthalmologic evaluation of patients with diabetic foot ulcer

Pérez RS, Barrero VL, Tamayo RM, David BM

Language: Spanish
References: 14
Page: 3-14
PDF size: 191.32 Kb.


ABSTRACT

Introduction: The prevalence of diabetes gradually increases worldwide and with it, the risk of microvascular complications such as diabetic retinopathy. The risk of blindness is reduced with stable metabolic control, early diagnosis and adequate treatment.
Objective: To compare the result of the ophthalmological examination performed before starting treatment with Heberprot-P, with that performed five months after initiation, at different doses.
Methods: A retrospective observational study was conducted in 77 patients included in four clinical trials of Heberprot-P. Analysis of the ophthalmological examination variables before and after treatment, type of diabetes and years of evolution were performed.
Results: Prevalence of type 2 diabetics was observed with respect to type 1 in an 11: 1 ratio, with an average of 16.3 years of diabetes evolution. Half of the patients had nonproliferative diabetic retinopathy, predominantly of the mild form, in the examination performed before treatment with Heberprot-P. Only one elderly patient with other comorbidities developed a proliferative diabetic retinopathy, after a previous examination in which non-proliferative diabetic retinopathy and diabetic macular edema were observed.
Conclusions: The appearance or progression of diabetic retinopathy is uncommon in complicated patients with diabetic foot ulcer treated with Heberprot-P, up to five months after treatment.


REFERENCES

  1. Rodríguez-Rodríguez B, Rodríguez-Rodríguez V. Retinopatía diabética, una epidemia prevenible y tratable. Rev Cubana Oftalmol. 2015[acceso: 22/06/2018]; 28(1): [aprox 1 p.]. Disponible en: https://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21762015000100001

  2. Barría von-Bischhoffshausen F, Martínez Castro F, Verdaguer Terradella J, editores. Actualización de la Guía clínica de Retinopatía Diabética para Latinoamérica. Texas: Asociación Panamericana de Oftalmologia; 2016 [acceso 22/06/2018]; 28 p. Disponible en: https://www.paao.org/images/Downloads/spanish/pdf/Guia-ClinicaRetinopatiaDiabetica2016.pdf

  3. Rodríguez-Rodríguez B, Rodríguez-Rodríguez V, Ramos-López M, Velázquez-Villares Y, Alemañi-Rubio E, González-Díaz RE, et al. Estrategia nacional para la prevención de ceguera por retinopatía diabética. Rev Cubana Oftalmol. 2015 [acceso 22/06/2018]; 28(1): [aprox. 5 p.]. Disponible en: https://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21762015000100014&lng=es

  4. Bui TQ, Bui QVP, Németh D, Hegyi P, Szakács Z, Rumbus Z, et al. Epidermal Growth Factor is Effective in the Treatment of Diabetic Foot Ulcers: Meta-Analysis and Systematic Review. Int J Environ Res Public Health. 2019 [acceso 25/02/2019]; 16(14): 2584. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/31331038

  5. Berlanga J , Fernández JI , López E , López PA , del Río A , Valenzuela C, et al. Heberprot-P: a novel product for treating advanced diabetic foot ulcer.MEDICC Rev. 2013 [acceso 25/02/2019]; 15(1):11-5. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/23396236/

  6. Fernández-Montequín JI, Infante-Cristiá E, Valenzuela-Silva C, Franco-Pérez N, Savigne-Gutiérrez W, Artaza-Sanz H, et al. Intra-lesional injections of Citoprot-P(r) (recombinant human Epidermal Growth Factor) in advanced diabetic foot ulcers with risk of amputation. Int Wound J. 2007 [acceso: 25/02/2019]; 4(4):333-43. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/17953679

  7. Pérez-Muñoz ME, Redondo-Piño LR, Maciques-Rodríguez JE. Nuestra experiencia en el enfoque integral de prevención y control de la retinopatía diabética. Rev Cubana Endocrinol. 2017 [acceso: 22/06/2018];28(2): [aprox. 2 p]. Disponible en: https://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532017000200008&lng=es

  8. Molina-Martín JC, Hernández-Silva Y, Molina-Martín LA. Factores de riesgos asociados a retinopatía diabética. Rev Cubana Oftalmol. 2006[acceso: 22/07/2018]; 19(2): [aprox 8 p.]. Disponible en: https://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21762006000200007&lng=es

  9. Rosabal-Crespo Y, Montes de Oca-Campos I, Hernández-Soria M, Céspedes-Galiano VS, Velázquez-Silva S. Factores de riesgo de la retinopatía diabética en pacientes mayores de 60 años. Rev. electron. Zoilo. 2014 [acceso: 22/06/2018]; 39(9): [aprox. 5 p]. Disponible en: https://revzoilomarinello.sld.cu/index.php/zmv/article/view/155/276

  10. Rodríguez-Rodríguez B. Prevención de ceguera por retinopatía diabética: ¿dónde estamos? Rev Cubana Oftalmol. 2015 [acceso: 22/06/2018]; 28(1): [aprox. 5 p]. Disponible en: https://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21762015000100013&lng=es

  11. Rodríguez-Rodríguez B, Rodríguez-Rodríguez V, Fernández-Gómez Y. La prevención de la discapacidad visual por retinopatía diabética: un reto para todos. Rev Cubana Oftalmol. 2017 [acceso: 22/06/2018]; 30(3): 1-8. Disponible en: https://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21762017000300014&lng=es

  12. Morffi-González E, Díaz-Díaz Y, Fernández-Pérez V, Peña-Hernández K, Pérez-Padilla CA. Retinopatía diabética en el adulto mayor. MEDICIEGO. 2013 [acceso: 22/06/2018]; 19(1):[aprox. 4 p]. Disponible en: https://bvs.sld.cu/revistas/mciego/vol19_01_13/articulos/t-9.html

  13. Pérez-Muñoz ME, Triana-Casado I, Pérez-Rodríguez L, Isas-Cordové M. Caracterización clínica de la retinopatía diabética en diabéticos tipo 2 atendidos en el Servicio de Retina del Centro Oftalmológico "Dr. Salvador Allende" de la Habana. MEDICIEGO. 2012[acceso: 22/06/2018]; 18(1):[aprox. 5 p.]. Disponible en: https://bvs.sld.cu/revistas/mciego/vol18_01_2012/articulos/t-8.html

  14. Castro-Cárdenas K, López-Dorta N, Rodríguez-Rivero D, Suárez-Pérez JC, Llerena-Rodríguez JA. Factores de riesgo y severidad de la retinopatía diabética. Rev Cubana Med Milit. 2013 [acceso: 22/06/2018]; 42(2):181-190. Disponible en: https://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0138-65572013000200007&lng=es




2020     |     www.medigraphic.com